AbbVie to Present at the Leerink Partners Global Healthcare Conference
Rhea-AI Summary
AbbVie (NYSE: ABBV) will participate in the Leerink Partners Global Healthcare Conference on Tuesday, March 10, 2026. Management will take part in a fireside chat at 10:20 a.m. Central Time. A live audio webcast will be available via AbbVie's Investor Relations site, with an archived edition posted later that day.
Positive
- None.
Negative
- None.
News Market Reaction – ABBV
In the Mar 3 session, ABBV declined 0.17%, reflecting a mild negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Mar 02 | Clinical trial win | Positive | +0.9% | Positive Phase 3 AFFIRM SKYRIZI Crohn’s data with strong remission rates. |
| Feb 24 | Conference appearance | Neutral | -0.5% | Participation in TD Cowen health care conference fireside chat. |
| Feb 23 | Capacity investment | Positive | +2.1% | Plans to invest $380M in new U.S. API facilities, adding 300 jobs. |
| Feb 20 | FDA approval | Positive | +0.2% | FDA approval of VENCLEXTA plus acalabrutinib combo for first-line CLL. |
| Feb 19 | Dividend declaration | Positive | -1.9% | Quarterly cash dividend of $1.73 per share with long-term growth track. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent fundamentally positive events (clinical win, FDA approval, capex, dividend) mostly saw modest positive or mixed price moves, with one notable dividend-related pullback.
Over recent weeks, AbbVie has reported several material developments: a positive Phase 3 Crohn’s disease result for SKYRIZI on Mar 2, 2026, a major $380 million API manufacturing investment with 300 jobs, an FDA approval for a VENCLEXTA–acalabrutinib CLL regimen, and a quarterly dividend of $1.73 per share. Those events produced mostly modest price gains, with a pullback following the dividend declaration. Today’s Leerink conference appearance fits the pattern of routine investor-relations outreach seen in the prior TD Cowen conference announcement.
AI-generated analysis. How Rhea-AI works. Not financial advice.
A live audio webcast of the presentation will be accessible through AbbVie's Investor Relations website at investors.abbvie.com. An archived edition of the session will be available later that day.
About AbbVie
AbbVie's mission is to discover and deliver innovative medicines and solutions that solve serious health issues today and address the medical challenges of tomorrow. We strive to have a remarkable impact on people's lives across several key therapeutic areas including immunology, neuroscience and oncology – and products and services in our Allergan Aesthetics portfolio. For more information about AbbVie, please visit us at www.abbvie.com. Follow @abbvie on LinkedIn, Facebook, Instagram, X and YouTube.
Media: Gabby Tarbert (224) 244-0111 | Investors: Liz Shea |
View original content:https://www.prnewswire.com/news-releases/abbvie-to-present-at-the-leerink-partners-global-healthcare-conference-302701106.html
SOURCE AbbVie